China’s New Formulary Coming; Little MNC Reactions In Large Hospitals
This article was originally published in PharmAsia News
China’s new Essential Drug List will likely be implemented not only in grassroots medical institutes, but also in large hospitals with minimal sales and usage ratios.
You may also be interested in...
Genentech pays $30m up front in a collaboration with Bicycle in a deal that could bring the UK biotech roughly $1.7bn in total. Also, deals involving Nimble, Seattle Genetics, Five Prime, Fresenius, Vifor, Yuhan, Imnewrun, Paratek, Almirall, MBD, AzothBio, Norgine, Faes, Aspen Pharmacare, Swixx.
Rutgers University professor testifies in support of bill directing the FDA to designate National Centers of Excellence in Continuous Manufacturing; other bills target generic labeling, orphan exclusivity and counterfeit devices.
Colgate expects a ‘modest negative impact’ from the coronavirus on its first quarter results, but it made contingency plans for longer-term impact. In a presentation at the CAGNY conference, CEO Noel Wallace discussed a new anti-aging toothpaste in China and the latest iteration of Colgate Optic White in the US.